Drug intelligence / Profile preview

AxS 007

Development stage: Preclinical
Lead developer: Nanocarry Therapeutics
Modality: Small Molecules

Overview

AxS 007 is an investigational antineoplastic agent being developed by Nanocarry Therapeutics, in collaboration with the National Cancer Institute (USA), for the treatment of brain metastases associated with HER2-positive breast cancer. It is classified as a new molecular entity and is currently in preclinical development. The precise mechanism of action has not been defined or disclosed publicly as of the latest updates. There are no reports of orphan drug designation or advanced clinical trials for this compound[3].

Beyond the preview

Go deeper on AxS 007.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AxS 007.

Explore the full profile